| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1012146293 |
| P356 | DOI | 10.1007/S13277-015-3211-Y |
| P698 | PubMed publication ID | 25677905 |
| P5875 | ResearchGate publication ID | 272239033 |
| P50 | author | Mohammad Safiqul Islam | Q57921212 |
| Muhammad Shahdaat Bin Sayeed | Q41177048 | ||
| Mir Muhammad Nasir Uddin | Q57089797 | ||
| P2093 | author name string | Abul Hasnat | |
| Salma Parvin | |||
| Md Siddiqul Islam | |||
| Maizbah Uddin Ahmed | |||
| Syed Md Akram Hussain | |||
| P2860 | cites work | Association between survival after treatment for breast cancer and glutathione S-transferase P1 Ile105Val polymorphism | Q73144127 |
| Polymorphisms within glutathione S-transferase genes (GSTM1, GSTT1, GSTP1) and risk of relapse in childhood B-cell precursor acute lymphoblastic leukemia: a case-control study | Q73426872 | ||
| The efficacy and safety of preoperative chemotherapy with triweekly abraxane and cyclophosphamide followed by 5-Fluorouracil, epirubicin, and cyclophosphamide therapy for resectable breast cancer: a multicenter clinical trial | Q86124086 | ||
| Pharmacogenetics of adjuvant breast cancer treatment with cyclophosphamide, epirubicin and 5-fluorouracil | Q87433062 | ||
| GSTT1, GSTM1, and GSTP1 polymorphisms as a prognostic factor in women with breast cancer | Q95528317 | ||
| Reconstructing Indian population history | Q21128684 | ||
| Pharmacogenetics, pharmacogenomics, and individualized medicine | Q23919667 | ||
| Molecular portraits of human breast tumours | Q28032461 | ||
| New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) | Q28131668 | ||
| Association study of genetic polymorphism in ABCC4 with cyclophosphamide-induced adverse drug reactions in breast cancer patients | Q28255901 | ||
| Oral combination chemotherapy with capecitabine and cyclophosphamide in patients with metastatic breast cancer: a phase II study | Q33387849 | ||
| Drug focus: Pharmacogenetic studies related to cyclophosphamide-based therapy | Q33646358 | ||
| Comparison of doxorubicin and cyclophosphamide versus single-agent paclitaxel as adjuvant therapy for breast cancer in women with 0 to 3 positive axillary nodes: CALGB 40101 (Alliance). | Q33927979 | ||
| Pharmacogenomics: the inherited basis for interindividual differences in drug response | Q34433440 | ||
| Gene polymorphisms in cyclophosphamide metabolism pathway,treatment-related toxicity, and disease-free survival in SWOG 8897 clinical trial for breast cancer | Q34682560 | ||
| Systematic evaluation of genetic variants in three biological pathways on patient survival in low-stage non-small cell lung cancer | Q35171191 | ||
| Improving outcomes from breast cancer in a low-income country: lessons from bangladesh | Q35684561 | ||
| Polymorphisms in genes involved in drug detoxification and clinical outcomes of anthracycline-based neoadjuvant chemotherapy in Chinese Han breast cancer patients | Q36009708 | ||
| Glutathione s-transferase p1: gene sequence variation and functional genomic studies | Q36798838 | ||
| An overview of the relations between polymorphisms in drug metabolising enzymes and drug transporters and survival after cancer drug treatment | Q37260809 | ||
| Multidrug resistance protein 4 (MRP4/ABCC4) mediates efflux of bimane-glutathione. | Q40612080 | ||
| Defining genetic architecture of the populations in the Indian subcontinent: Impact of human leukocyte antigen diversity studies | Q41454568 | ||
| Milestones in breast cancer treatment | Q41705329 | ||
| ABCC4 is required for cell proliferation and tumorigenesis in non-small cell lung cancer | Q41983373 | ||
| GSTT1, GSTM1, and GSTP1 polymorphisms and chemotherapy response in locally advanced breast cancer | Q43010096 | ||
| Genotype frequencies of selected drug metabolizing enzymes and ABC drug transporters among breast cancer patients on FAC chemotherapy. | Q43183931 | ||
| Polymorphic variation in GSTP1 modulates outcome following therapy for multiple myeloma. | Q44468885 | ||
| Genetic polymorphisms in glutathione-S-transferase genes (GSTM1, GSTT1, GSTP1) and survival after chemotherapy for invasive breast carcinoma | Q45163885 | ||
| Association of CYP3A4, CYP3A5 polymorphisms with lung cancer risk in Bangladeshi population | Q46175794 | ||
| Glutathione S-transferase P1 genotype and prognosis in Hodgkin's lymphoma | Q46402536 | ||
| Pharmacogenetic influence of GST polymorphisms on anthracycline-based chemotherapy responses and toxicity in breast cancer patients: a multi-analytical approach. | Q50868086 | ||
| Lung cancer risk in relation to TP53 codon 47 and codon 72 polymorphism in Bangladeshi population. | Q54198614 | ||
| Lung cancer risk in relation to nicotinic acetylcholine receptor, CYP2A6 and CYP1A1 genotypes in the Bangladeshi population. | Q54282377 | ||
| Polymorphisms of GSTP1 is associated with differences of chemotherapy response and toxicity in breast cancer. | Q54385308 | ||
| P433 | issue | 7 | |
| P921 | main subject | Bangladesh | Q902 |
| P304 | page(s) | 5451-5457 | |
| P577 | publication date | 2015-02-13 | |
| P1433 | published in | Tumor Biology | Q15757842 |
| P1476 | title | Effect of GSTP1 and ABCC4 gene polymorphisms on response and toxicity of cyclophosphamide-epirubicin-5-fluorouracil-based chemotherapy in Bangladeshi breast cancer patients | |
| P478 | volume | 36 |
| Q50909910 | Association of BRCA1, BRCA2, RAD51, and HER2 gene polymorphisms with the breast cancer risk in the Bangladeshi population. |
| Q41051383 | Breast cancer risk in relation to TP53 codon 72 and CDH1 gene polymorphisms in the Bangladeshi women |
| Q42700718 | GSTP1 polymorphism predicts treatment outcome and toxicities for breast cancer |
| Q38376375 | GSTP1, GSTM1, and GSTT1 polymorphisms as predictors of response to chemotherapy in patients with breast cancer: a meta-analysis |
| Q49678698 | Independent replication of polymorphisms predicting toxicity in breast cancer patients randomized between dose-dense and docetaxel-containing adjuvant chemotherapy. |
| Q51744122 | Pharmacogenetics of toxicity of 5-fluorouracil, doxorubicin and cyclophosphamide chemotherapy in breast cancer patients. |
| Q38791215 | Pharmacogenomics of second-line drugs used for treatment of unresponsive or relapsed osteosarcoma patients. |
Search more.